使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings, and welcome to Align Q4 2017 Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to our host, Shirley Stacy. Please go ahead.
各位好,歡迎參加 Align 2017 年第四季財報電話會議。(接線員指示) 提醒各位,本次會議將被錄音。現在我想把會議交給我們的主持人 Shirley Stacy。請開始。
Shirley Stacy
Shirley Stacy
Good afternoon, and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and John Morici, CFO. We issued fourth quarter and full year 2017 financial results today via Market Wire, which is available on our website at investor.aligntech.com. Today's conference call is being audio webcast and will be archived on our website for approximately 12 months. A telephone replay will be available today by approximately 5:30 p.m. Eastern time through 5:30 p.m. Eastern time on February 13. To access the telephone replay, domestic callers should dial (877) 660-6853, with conference number 13674959, followed by #. International callers should dial (201) 612-7415, with the same conference number.
各位下午好,感謝各位加入我們。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同參與電話會議的有總裁暨執行長 Joe Hogan,以及財務長 John Morici。我們今天已透過 Market Wire 發布 2017 年第四季及全年財務結果,可於我們網站 investor.aligntech.com 取得。今天的電話會議將以音訊網路直播,並將在我們網站上封存約 12 個月。電話重播將於今日約下午 5:30(美東時間)提供,並持續至 2 月 13 日下午 5:30(美東時間)。如需收聽電話重播,美國境內來電者請撥 (877) 660-6853,會議號碼 13674959,然後按 #。國際來電者請撥 (201) 612-7415,會議號碼相同。
As a reminder, the information that the presenters discuss today will include forward-looking statements, including statements about Align's future events, product outlook and the expected financial results for the first quarter and full year outlook for 2018. These forward-looking statements are only predictions and involve risks and uncertainties that are set forth in more detail in our most recent periodic reports filed with the Securities and Exchange Commission. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statements. We've posted historical financial statements, including the corresponding reconciliations and our fourth quarter conference call slides on our website, under Quarterly Results. Please refer to these files for more detailed information. With that, I'll turn the call over into Align Technology's President and CEO, Joe Hogan. Joe?
提醒各位,今天簡報人員所討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望,以及 2018 年第一季與全年預期財務結果的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容已在我們最近向美國證券交易委員會提交的定期報告中更詳細說明。實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述的義務。我們已在網站「季度結果」專區張貼歷史財務報表(含相應調節表)以及第四季電話會議簡報投影片。請參閱這些檔案以取得更詳細資訊。接下來,我將把電話會議交給 Align Technology 總裁暨執行長 Joe Hogan。Joe?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Thanks, Shirley. Good afternoon, and thanks for joining us. On our call today, I'll provide some highlights for the quarter and then briefly discuss the performance of our 2 operating segments, clear aligners and intra-oral scanners. John will provide more detail on our financial results and discuss our outlook for the first quarter and how we see 2018 unfolding. Following that, I'll come back and summarize a few key points and open up the call to questions.
謝謝你,Shirley。各位下午好,感謝各位加入我們。在今天的電話會議中,我將先提供本季的一些重點,接著簡要說明我們兩個營運部門——透明牙套與口內掃描器——的表現。John 將更詳細說明我們的財務結果,並討論第一季展望以及我們對 2018 年走勢的看法。之後我會回來總結幾個關鍵重點,並開放提問。
Overall, the fourth quarter was a strong finish to another outstanding year for Align with better-than-expected revenues, volumes and operating income. Record Q4 revenues were up 43.7% year-over-year, driven by an increase in Invisalign volumes across all geographies and customer channels as well as by record iTero Scanner revenues. Q4 Invisalign volume was up 34.2% year-over-year, reflecting strong international growth from increased utilization and expansion of our customer base, which included over 4,000 new customers for the third consecutive quarter. Notwithstanding this strong performance, our Q4 results were impacted by the new U.S. Tax Cuts and Jobs Act, which reduced our reported net income and EPS. However, Q4 operating income was a record $109.6 million or 26%. John will discuss this in more detail in his section in a few minutes. For the full year, revenue of $1.5 billion increased 36.4% year-over-year, driven by both record Invisalign revenue, which surpassed the $1 billion mark for the first time ever, and record iTero Scanner revenues. These results reflect continued progress and execution of our 4 strategic growth drivers, which focus on driving international expansion, increasing orthodontist utilization of Invisalign, especially with teenagers; enabling GP dentists to treat and refer more Invisalign cases; and generating consumer demand for millions of people worldwide and connecting them with an Invisalign doctor.
整體而言,第四季為 Align 又一個傑出年度畫下強勁句點,營收、出貨量與營業利益均優於預期。第四季營收創新高,年增 43.7%,主要受惠於各地區與各客戶通路的 Invisalign 出貨量增加,以及 iTero 掃描器營收同創新高。第四季 Invisalign 出貨量年增 34.2%,反映國際市場因使用率提升與客戶基礎擴張而帶來的強勁成長;其中連續第三季新增超過 4,000 名新客戶。儘管表現強勁,我們第四季結果仍受到美國《減稅與就業法案》影響,導致我們報導的淨利與每股盈餘(EPS)下降。然而,第四季營業利益創新高,達 1.096 億美元,或 26%。John 將在稍後的段落中更詳細說明。全年方面,營收 15 億美元,年增 36.4%,主要由 Invisalign 營收與 iTero 掃描器營收雙雙創新高所帶動;其中 Invisalign 營收更是史上首次突破 10 億美元。這些成果反映我們在四大策略性成長驅動因素上的持續進展與執行力:推動國際擴張、提高矯正醫師對 Invisalign 的使用率(尤其在青少年族群)、協助一般牙醫(GP)治療並轉介更多 Invisalign 病例,以及在全球為數百萬消費者創造需求並將其連結至 Invisalign 醫師。
Turning to the specifics around our fourth quarter results. Let's start with results of our North American region. For North America, Q4 was a good quarter with Invisalign case volume up 5.1% sequentially and 24.2% year-over-year. Sequential growth primarily reflects a seasonality -- a seasonally stronger period for GP dentists as patient activities in their offices increase after summer holidays. Ortho customers treated more adult patients following the busy teen season. In addition, Q4 Invisalign utilization increased to 3.3 cases per GP dentist, and North American orthos received a record 14 cases per doctor, reflecting continued confidence and uptake of the Invisalign system. On a year-over-year basis, strong growth was driven primarily by an increased ortho utilization and continued expansion of our GP customer base.
接著說明第四季結果的細節。先從北美地區的表現談起。在北美,第四季表現良好,Invisalign 病例量季增 5.1%,年增 24.2%。季增主要反映季節性因素——對一般牙醫而言,暑假後病患回流、診所活動增加,使第四季通常較為強勁。矯正客戶在青少年旺季後,治療更多成人病患。此外,第四季 Invisalign 使用率提升至每位一般牙醫 3.3 例,而北美矯正醫師每位醫師收到創紀錄的 14 例,反映市場對 Invisalign 系統的持續信心與採用提升。以年對年來看,強勁成長主要由矯正醫師使用率提升,以及我們一般牙醫客戶基礎持續擴張所帶動。
For the full year, both North America orthos and GP dentists achieved record annualized utilization of 47 and 8 cases per doctor, respectively. For international doctors, Q4 was another strong quarter with Invisalign case volume up 12.7% sequentially and 52.3% year-over-year. Sequential growth reflects a seasonally stronger quarter for EMEA region following summer holidays for doctors and patients, which offset expected decreases from seasonality in APAC, particularly as the greater China market observed local holidays.
全年而言,北美矯正醫師與一般牙醫的年化使用率分別達到每位醫師 47 例與 8 例,雙雙創下新高。國際醫師方面,第四季同樣強勁,Invisalign 病例量季增 12.7%,年增 52.3%。季增反映 EMEA 地區在醫師與病患暑假後進入季節性較強的季度,抵銷了 APAC 因季節性而預期下滑的影響,尤其是大中華區市場逢當地假期。
On a year-over-year basis, strong Invisalign volume was driven by growth from both EMEA and the Asia Pacific region. Year-over-year growth for EMEA was up 42.9%, led by Spain, France and the U.K. We also saw strong growth across all of our smaller expansion markets, which include Central and Eastern Europe, the Middle East and Africa. In APAC, Q4 volumes were up 63% year-over-year, led by China, Japan and Australia, with record Invisalign volume in most APAC countries.
以年對年來看,Invisalign 病例量的強勁成長來自 EMEA 與亞太地區的雙重帶動。EMEA 年增 42.9%,由西班牙、法國與英國領軍。我們也看到所有較小的擴張市場均有強勁成長,包括中東歐、中東與非洲。在 APAC,第四季出貨量年增 63%,由中國、日本與澳洲帶動,多數 APAC 國家均創下 Invisalign 出貨量新高。
For the full year, Invisalign volume increased 44.9% led by growth from China and our core EMEA country markets. In total, international volume represented 38% of worldwide Invisalign case shipments.
全年 Invisalign 出貨量增加 44.9%,主要由中國與我們 EMEA 核心國家市場的成長所帶動。整體而言,國際出貨量占全球 Invisalign 病例出貨的 38%。
Now turning to the teen market, which makes up 75% of total orthodontic case starts each year. In Q4, 63,500 teenagers started treating with Invisalign clear aligners, an increase of 44.1% year-over-year, driven by continued strong adoption across all major regions and increasingly for younger teens and tweens. For Q4, year-over-year Invisalign teen patient growth for North America orthos increased 37.8% and international was up 64.7%. Notwithstanding some seasonality during the quarter, given fewer teen case starts, Q4 was the fifth consecutive quarter that Invisalign teenage patient volume grew faster than adults. On a sequential basis, North American ortho teen cases were down as expected as our ortho customers shifted their focus towards adult patient case starts in Q4 following a very busy summer teen season.
接著談青少年市場;該市場每年約占所有矯正病例啟動量的 75%。第四季有 63,500 名青少年開始使用 Invisalign 透明牙套治療,年增 44.1%,主要受惠於各主要地區持續強勁的採用,以及在更年輕的青少年與學齡前後(tweens)族群中的滲透提升。第四季,北美矯正醫師的 Invisalign 青少年病患量年增 37.8%,國際市場年增 64.7%。儘管本季因青少年病例啟動量較少而存在部分季節性因素,第四季仍是 Invisalign 青少年病患量連續第五季成長速度快於成人。以季對季來看,北美矯正醫師的青少年病例如預期下滑,因為在非常繁忙的夏季青少年旺季之後,我們的矯正客戶在第四季將重心轉向成人病患的病例啟動。
For the full year, a total of 237,000 teenagers or 26% of our total volume started treatment with Invisalign clear aligners, up 40.4% from 2016. During the year, we continue to drive adoption of teenage patients through sales and marketing programs, including a major new direct-to-consumer campaign, emphasizing teens and moms. In addition, at the beginning of 2017, we launched the first clear aligners solution for Class II correction that combines all the benefits of the most advanced clear aligner system in the world, with features for moving the lower jaw forward while simultaneously aligning the teeth. Invisalign teen with mandibular advancement, or MAF as we call it, offers a simpler, more efficient and patient-friendly option than functional appliances. MAF was launched in certain country markets in Canada, EMEA and APAC and is ramping up nicely across-the-board, especially in China. To date, we have shipped over 5,000 MAF cases outside the United States, half of which were in Q4 alone. And we're very excited about the potential for MAF worldwide, however, we do not expect any material contribution in the U.S. for MAF until the back half of 2018 as we continue to work through the 510(k) regulatory approval process with the FDA, which includes collecting additional data and analysis.
就全年而言,共有237,000名青少年(占我們總量的26%)開始使用Invisalign隱形矯正器治療,較2016年成長40.4%。在這一年中,我們持續透過銷售與行銷方案推動青少年患者的採用,包括一項重大的全新直接面向消費者(DTC)行銷活動,重點鎖定青少年與媽媽族群。此外,在2017年初,我們推出了首個用於II類咬合(Class II)矯正的隱形矯正器解決方案,結合全球最先進隱形矯正系統的所有優勢,並具備在同時排列牙齒的同時將下顎向前移動的功能。我們稱之為具下顎前移功能的Invisalign teen(mandibular advancement),或簡稱MAF,相較於功能性矯治器,提供更簡單、更高效率且更友善於患者的選擇。MAF已在加拿大、EMEA與APAC的部分國家市場推出,並在各市場穩健加速成長,尤其是在中國。截至目前,我們在美國以外已出貨超過5,000例MAF病例,其中一半僅在第四季(Q4)出貨。我們對MAF在全球的潛力感到非常振奮;然而,由於我們仍在與FDA進行510(k)法規核准流程(包括蒐集額外資料與分析),預期在2018年下半年之前,MAF在美國不會帶來任何實質性的貢獻。
The Invisalign brand is one of the most recognized in the dental and orthodontic market. Our integrated consumer marketing programs leverage traditional pay media, search, digital marketing, PR and social media to engage consumers at every point in the consumer purchase journey. These programs continue to drive demand for Invisalign treatment and are key to adoption in both the teen and adult segments.
Invisalign品牌是牙科與齒顎矯正市場中最廣為人知的品牌之一。我們整合式的消費者行銷方案運用傳統付費媒體、搜尋、數位行銷、公關與社群媒體,在消費者購買旅程的每一個接觸點與消費者互動。這些方案持續帶動對Invisalign治療的需求,並且是青少年與成人兩大族群採用的關鍵。
In 2017, we launched a new Made to Move brand platform for Invisalign, which has been really impactful around the world. In North America, we expanded our traditional digital media campaigns targeting both men and women for the first time and made a significant investment in our marketing to teens and moms. We stepped up our approach to teens by partnering with content developers, teen and mom social media influencers and teen brands like AwesomenessTV, which we saw pay off in increases in our consumer website activity and opt-in metrics. We also saw a positive impact from the global Made to Move campaign across EMEA and APAC. EMEA focused heavily on digital, social and web traffic, which resulted in huge increase in their online Smile Assessments and other KPIs. APAC markets like Singapore and Australia also saw an increase in KPIs based on their focus on social media and local event and influencer-driven marketing. As a result, in total for the year, there were over 15 million unique visitors to the Invisalign websites worldwide. 1.8 million potential patients searched for an Invisalign provider on doc locator, up 41% from 2016. 600,000 consumers completed Invisalign Smile Assessments on our website, of which, 445,000 opted in for follow-up and the Invisalign social media community grew over 42% to 745,000 consumers following the Invisalign brand worldwide.
2017年,我們為Invisalign推出全新的「Made to Move」品牌平台,並在全球產生了非常顯著的影響。在北美,我們首次擴大傳統數位媒體活動,同時鎖定男性與女性,並大幅加碼對青少年與媽媽族群的行銷投資。我們透過與內容開發者、青少年與媽媽社群媒體意見領袖,以及AwesomenessTV等青少年品牌合作,強化對青少年的策略;我們也看到成效反映在消費者網站活動與選擇加入(opt-in)指標的提升。我們也看到全球「Made to Move」活動在EMEA與APAC帶來正面影響。EMEA高度聚焦於數位、社群與網站流量,帶動其線上「Smile Assessments」及其他KPI大幅成長。APAC市場(如新加坡與澳洲)也因聚焦社群媒體以及在地活動與意見領袖帶動的行銷,而看到KPI提升。因此,全年合計,全球Invisalign網站的獨立訪客超過1,500萬人。有180萬名潛在患者透過醫師查找工具(doc locator)搜尋Invisalign提供者,較2016年成長41%。有600,000名消費者在我們網站完成Invisalign Smile Assessments,其中445,000人選擇加入後續追蹤;同時,Invisalign社群媒體社群規模成長逾42%,達到745,000名在全球追蹤Invisalign品牌的消費者。
You may recall that in January last year, we launched a new Smile Concierge program in Raleigh, North Carolina, with the objective to help more consumers start Invisalign treatment and improve their overall experience by shortening their research cycles and utilizing consumer insights to help our doctors better engage with consumers. Throughout the year, we made great progress from ongoing program improvements in December. We achieved a major milestone with the 6,500 Invisalign patient for the Smile Concierge team. Cumulatively, we scheduled over 26,000 Invisalign consultations, which equates to connecting hundreds of consumers to Invisalign practices every day. We continue to see incredible potential as our doctor's offices are implementing changes to better engage with consumers that we send to them every day. We've also started to expand the Smile Concierge service outside the United States with our first teams up and running in Singapore, Brazil and Australia, with each of these countries having a great start to the year, helping more consumers become Invisalign patients. Over the course of the year, we'll update you on our continued progress in leveraging important learnings about consumer behavior and establishing Smile Concierge teams in EMEA and Asia Pacific regions. In 2018, our Smile Concierge team will be very closely linked to the new Invisalign store pilot that we opened in November, which we utilize our consumer insights to better capture leads coming out of the store experience. The Smile Concierge team will be utilizing our touch point learnings to reach out to consumers who receive a scan but don't schedule an appointment with the doctor. In addition, we'll use our automated text and e-mail services to remind consumers when and where to pick up their aligners or to see a doctor as scheduled. These are just a few of the exciting new ways that we're helping to educate consumers on the benefits of getting a better smile with Invisalign treatment and connect them with an Invisalign doctor of their choice. The Invisalign store pilot program that launched in November is an extension of our long-standing direct-to-consumer marketing programs that connect potential patients directly to doctors for Invisalign treatment. We're looking to other successful brands and how they use a physical location to engage consumers and extend the brand experience. In this case, we are trying to extend and strengthen what we do through digital ads, social media, PR and TV advertising and our customer's own in-practice patient marketing. Our pilot store model relies on the doctor and the doctor's office for treatment. We are not treating patients in the store. Instead, we are educating consumers on how Invisalign works, showing them a scan-driven simulation of how they might look with straighter teeth and offering to connect interested consumers with a doctor of their choice should they subsequently decide to pursue treatment. To date, we've learned a lot about creating the right consumer experience with the Invisalign system through a storefront and are continuing to evolve and make continued progress.
您可能還記得,去年1月我們在北卡羅來納州羅利(Raleigh)推出全新的Smile Concierge計畫,目標是協助更多消費者開始Invisalign治療,並透過縮短研究決策週期、運用消費者洞察協助醫師更有效與消費者互動,以提升整體體驗。在這一年中,我們透過持續的計畫改善,並在12月取得了很大進展。Smile Concierge團隊達成一項重要里程碑:服務第6,500位Invisalign患者。累計而言,我們安排了超過26,000次Invisalign諮詢,等同於每天為數百名消費者媒合至Invisalign診所。我們持續看到巨大的潛力,因為醫師診所正在落實變革,以更好地與我們每天導入給他們的消費者互動。我們也開始將Smile Concierge服務拓展至美國以外地區,首批團隊已在新加坡、巴西與澳洲開始運作;這些國家在年初都有很好的起步,協助更多消費者成為Invisalign患者。在接下來一年中,我們將持續向您更新我們在運用消費者行為重要洞察,以及在EMEA與亞太地區建立Smile Concierge團隊方面的進展。2018年,我們的Smile Concierge團隊將與我們於11月開設的全新Invisalign門市試點(pilot)緊密連結,我們將運用消費者洞察,更有效捕捉門市體驗所產生的潛在客戶名單(leads)。Smile Concierge團隊將運用我們在各接觸點的學習,主動聯繫已完成掃描但未與醫師預約的消費者。此外,我們將使用自動化簡訊與電子郵件服務,提醒消費者在何時何地領取矯正器,或依預定時間就診。以上只是我們以幾種令人振奮的新方式,協助教育消費者了解透過Invisalign治療獲得更美笑容的益處,並將他們與其選擇的Invisalign醫師連結。11月推出的Invisalign門市試點計畫,是我們長期直接面向消費者行銷方案的延伸,該方案可將潛在患者直接連結至醫師以接受Invisalign治療。我們也參考其他成功品牌如何運用實體據點與消費者互動並延伸品牌體驗。在此案例中,我們嘗試延伸並強化我們透過數位廣告、社群媒體、公關與電視廣告,以及客戶在診所內自有的患者行銷所做的工作。我們的試點門市模式仍仰賴醫師與其診所提供治療。我們不在門市為患者進行治療。相反地,我們向消費者說明Invisalign的運作方式,展示以掃描為基礎的模擬,讓他們看到牙齒更整齊後可能的外觀,並在其後續決定接受治療時,提供協助將有興趣的消費者連結至其選擇的醫師。截至目前,我們已透過門市前台(storefront)在打造合適的Invisalign系統消費者體驗方面學到很多,並持續演進與取得進展。
In Q1, we will open another pilot store in San Jose, California near our corporate headquarters. We're planning to open 2 additional pilot stores on the East Coast sometime in the first half of this year. We look forward to continuing to learn more from these 4 locations and sharing our progress throughout the year.
在第一季(Q1),我們將在加州聖荷西(San Jose)靠近公司總部的地點再開設一家試點門市。我們計畫在今年上半年於美國東岸再開設2家額外的試點門市。我們期待持續從這4個據點獲得更多學習,並在全年與您分享我們的進展。
Q4 was a strong quarter for iTero and better-than-expected with revenues up 30.8% sequentially and 37% year-over-year on record iTero Scanner shipments. Q4 results reflect continued strength in our GP channel following our GP Summit in September as well as sales to our major DSO partners and through our iTero distributor, Patterson Dental. The iTero Scanner business was also strong in EMEA and has been growing rapidly in Asia Pacific, especially Japan where we received certification for iTero in Q3. Customers are quickly realizing the significant benefit of our iTero Scanner platform, and we are excited about the opportunity to continue to expand iTero's footprint worldwide. The iTero Scanner is central to our digital approach and overall customer utilization of Invisalign treatment. Use of the iTero scanners for Invisalign case shipments in place of PVS impressions continues to expand and remains a positive catalyst for Invisalign utilization. For Q4, total Invisalign cases submitted with a digital scanner in North America increased to a record 64.1%, up from 51.3% in Q4 last year. International scans increased to 40.8%, up from 24.9% in Q4 of last year. Not only does the iTero Scanner provide the best workflow for Invisalign treatment with the Invisalign outcome simulator and progress assessment tool, but it also seamlessly integrates with downstream restorative workflows, significantly improving their accuracy and precision. iTero is also the only scanner with TimeLapse technology that makes chair-side consults more productive. By scanning patients at every visit using TimeLapse and comparing historical scans to a current scan, patients see for themselves the changes in their tooth wear, tooth movement and changes in gingiva over time, encouraging them to accept treatment right at chair side. In Q4, we cited a distribution agreement with Glidewell Dental for an iTero Element scanner in North America with glidewell.io, the in-office solution, a chair-side restorative ecosystem designed to simplify the process of prescribing and delivering laboratory-quality dental restorations.
第四季對 iTero 而言是強勁的一季,且優於預期;在 iTero 掃描器出貨量創新高的帶動下,營收較前一季成長 30.8%,較去年同期成長 37%。第四季的結果反映出我們在 9 月舉辦 GP 高峰會後,GP 通路持續展現強勁動能,以及對主要 DSO 合作夥伴的銷售,並透過我們的 iTero 經銷商 Patterson Dental 進行銷售。iTero 掃描器業務在 EMEA 也表現強勁,並在亞太地區快速成長,尤其是日本,我們在第三季取得 iTero 的認證。客戶正迅速意識到我們 iTero 掃描器平台的重大效益,我們也對持續擴大全球 iTero 版圖的機會感到振奮。iTero 掃描器是我們數位化策略的核心,也是客戶整體 Invisalign 療程使用度的關鍵。以 iTero 掃描器用於 Invisalign 病例出貨、取代 PVS 印模的使用持續擴大,並仍是推動 Invisalign 使用度的正向催化因素。第四季,北美使用數位掃描器提交的 Invisalign 病例占比提升至創紀錄的 64.1%,高於去年第四季的 51.3%。國際市場的掃描占比提升至 40.8%,高於去年第四季的 24.9%。iTero 掃描器不僅透過 Invisalign 結果模擬器與進度評估工具,為 Invisalign 療程提供最佳工作流程,亦可與後端修復工作流程無縫整合,顯著提升其準確度與精密度。iTero 也是唯一具備 TimeLapse 技術、能讓椅旁諮詢更具生產力的掃描器。透過在每次回診使用 TimeLapse 為患者掃描,並將歷史掃描與當前掃描比較,患者可親眼看到牙齒磨耗、牙齒移動以及牙齦隨時間的變化,進而促使其在椅旁即刻接受治療。在第四季,我們提到與 Glidewell Dental 在北美就 iTero Element 掃描器簽訂經銷協議,並結合院內解決方案 glidewell.io——一個椅旁修復生態系,旨在簡化開立處方與交付具實驗室品質之牙科修復體的流程。
In 2017, iTero scanners volumes were up 37.5% year-over-year. Today, there are over 6.3 million orthodontic scans and 2.4 million restorative scans have started with iTero scanners. Finally, in the doc-directed, at-home channel, Align is a third party supplier to SmileDirectClub and has 19% equity investment in the company. We manufacture a portion of SDC aligners with non-Invisalign clear aligners. The Q4 shipments to SDC were down sequentially, as expected, as SDC increased their own internal capacity. As an investor and supplier to SDC, Align is focused on 2 things: expanding the market for orthodontic treatment and providing greater access to simple teeth straightening solutions to millions of more people who prioritize convenience and affordability; and creating new opportunities for Invisalign doctors by connecting consumers who aren't candidates for SDC's limited protocols to an Invisalign practice. With that, I'll now turn the call over to John.
2017 年,iTero 掃描器出貨量較去年同期成長 37.5%。截至今日,已有超過 630 萬次矯正掃描與 240 萬次修復掃描是由 iTero 掃描器啟動。最後,在醫師導向的居家通路方面,Align 是 SmileDirectClub 的第三方供應商,並持有該公司 19% 的股權投資。我們生產部分 SDC 隱形牙套,屬於非 Invisalign 的透明牙套產品。如預期,第四季對 SDC 的出貨較前一季下滑,因為 SDC 提升了其內部產能。作為 SDC 的投資人與供應商,Align 聚焦兩件事:擴大正畸治療市場,並讓重視便利性與可負擔性的數百萬人更容易取得簡易牙齒矯正解決方案;以及透過將不符合 SDC 有限治療方案的消費者導流至 Invisalign 診所,為 Invisalign 醫師創造新機會。接下來,我把電話交給 John。
John F. Morici - CFO
John F. Morici - CFO
Thanks, Joe. Now for our Q4 financial results. Total company revenue for the fourth quarter was a record $421.3 million, up 9.4% from the prior quarter and up 43.7% from the corresponding quarter a year ago. Clear aligner revenue of $364.2 million was up 6.6% sequentially on higher-than-expected volume. Year-over-year clear aligner revenue growth of 44.8% reflected strong Invisalign shipment growth across all customer channels and geographies and increased Invisalign prices.
謝謝,Joe。接著說明我們第四季的財務結果。第四季公司總營收創紀錄,達 4.213 億美元,較前一季成長 9.4%,較去年同期成長 43.7%。透明牙套營收為 3.642 億美元,因出貨量高於預期,較前一季成長 6.6%。透明牙套營收年增 44.8%,反映 Invisalign 在所有客戶通路與各地區的出貨成長強勁,以及 Invisalign 價格上調。
Q4 Invisalign ASPs were down sequentially, approximately $5 from Q3 to $1,305, reflecting higher deferrals related to additional aligners and higher promotional discounts, partially offset by international price increases. On a year-over-year basis, Q4 Invisalign ASPs were up approximately $75, reflecting price increases, favorable foreign exchange, product mix as well as the impact of discontinuing distribution and going directly in several regions, partially offset by increased promotional discounts and higher deferrals related to additional aligners. For the fourth quarter, total Invisalign shipments of 255,000 cases were up 8% sequentially, driven by our EMEA and North America customers. Year-over-year, Invisalign case volume growth was up 34.2%, driven by growth across all regions. For North American orthodontists, Q4 Invisalign case volume was up 2.3% sequentially and up 30.7% year-over-year. For North American GP dentists, Invisalign case volume was up 9.2% sequentially and up 16.1% year-over-year. For international doctors, Invisalign case volume was up 12.7% sequentially and up 52.3% year-over-year. Our scanner and services revenue for the fourth quarter was $57.1 million, up 30.8% sequentially and up 37% year-over-year, primarily due to continued global investment in go-to-market activities and sales promotions as well as shipments to key DSO partners and our U.S. distributor, Patterson Dental.
第四季 Invisalign 平均銷售單價(ASP)較前一季下滑,約較第三季減少 5 美元至 1,305 美元,反映與追加牙套相關的遞延增加及促銷折扣提高;部分被國際市場漲價所抵銷。以年對年來看,第四季 Invisalign ASP 約增加 75 美元,反映價格上調、有利的外匯、產品組合,以及在若干地區停止經銷改採直營的影響;部分被促銷折扣增加與追加牙套相關遞延提高所抵銷。第四季 Invisalign 總出貨量為 255,000 例,較前一季成長 8%,主要由 EMEA 與北美客戶帶動。年對年而言,Invisalign 病例量成長 34.2%,由各區域成長所驅動。就北美矯正專科醫師而言,第四季 Invisalign 病例量較前一季成長 2.3%,較去年同期成長 30.7%。就北美 GP 牙醫而言,Invisalign 病例量較前一季成長 9.2%,較去年同期成長 16.1%。就國際醫師而言,Invisalign 病例量較前一季成長 12.7%,較去年同期成長 52.3%。第四季掃描器與服務營收為 5,710 萬美元,較前一季成長 30.8%,較去年同期成長 37%,主要由於持續在全球投入上市推廣(go-to-market)活動與銷售促銷,以及對關鍵 DSO 合作夥伴與我們美國經銷商 Patterson Dental 的出貨。
Moving on to gross margin. Fourth quarter overall gross margin was 75.5%, down 0.4 points sequentially and up 0.4 points year-over-year. Clear aligner gross margin for the fourth quarter was 77.6%, down 0.3 points sequentially, primarily due to higher manufacturing spend, driven by operational expansion activities. Clear aligner gross margin was up 0.1 points year-over-year, primarily due to increased ASPs and partially offset by higher manufacturing spend. Scanner gross margin for the fourth quarter was 62%, up 2 points sequentially and up 1 point year-over-year, primarily due to higher manufacturing efficiencies. Q4 operating expenses were $208.3 million, up sequentially 7.5% and up 37.2% year-over-year, primarily due to increased employee headcount and continued investment in our go-to-market activities critical to the growth of our (inaudible). Our fourth quarter operating income was a record $109.6 million, up 11% sequentially and up 60.3% year-over-year. Our fourth quarter operating margin was 26%, up 0.4 points sequentially and up 2.7 points year-over-year. The sequential increase in operating margin relates primarily to leverage, operating spend in sales and marketing off higher volumes, partially offset by lower gross margin due to operational expansion activities.
接著談毛利率。第四季整體毛利率為 75.5%,較前一季下降 0.4 個百分點,較去年同期上升 0.4 個百分點。第四季透明牙套毛利率為 77.6%,較前一季下降 0.3 個百分點,主要因製造支出增加,係由營運擴張活動所驅動。透明牙套毛利率年對年上升 0.1 個百分點,主要因 ASP 提高,部分被製造支出增加所抵銷。第四季掃描器毛利率為 62%,較前一季上升 2 個百分點,較去年同期上升 1 個百分點,主要因製造效率提升。第四季營業費用為 2.083 億美元,較前一季增加 7.5%,較去年同期增加 37.2%,主要因員工人數增加,以及持續投資於對我們(聽不清)成長至關重要的上市推廣活動。第四季營業利益創紀錄,達 1.096 億美元,較前一季成長 11%,較去年同期成長 60.3%。第四季營業利益率為 26%,較前一季上升 0.4 個百分點,較去年同期上升 2.7 個百分點。營業利益率的季增主要與規模效益(leverage)有關,在出貨量提高下,銷售與行銷的營運支出攤提改善;部分被營運擴張活動導致的毛利率下降所抵銷。
On a year-over-year basis, the increase in operating margin primarily reflects higher revenues from both clear aligner and scanner and services, which created operating expense leverage. With regards to our fourth quarter tax provision, our tax rate was 92.4% and is up by 72.6 points compared to 19.8% in the same quarter last year, which includes $86.6 million in tax expense as a result of the U.S. Tax Cuts and Jobs Act enacted on December 22, 2017. This is comprised of $76.6 million of mandatory deemed repatriation tax on foreign -- on accumulated foreign earnings not previously taxed by the U.S. that we expect to pay over the next 8 years, and $10 million noncash write-down of our deferred tax assets due to the statutory tax rate decrease from 35% to 21%. Going forward, we may repatriate cash back to the U.S. to invest in market expansion opportunities, provide additional working capital and have greater flexibility to fund our stock repurchase program. In accordance with the SEC Staff Accounting Bulletin No. 118, we have recorded provisional amounts in the Q4 financial statements for certain income tax effects of the Act based on reasonable estimates and information available at the close of the period. We may adjust and refine the provisional amounts over the next year when additional information, analysis and legislative guidance becomes available.
以年對年基礎來看,營業利益率的提升主要反映透明牙套以及掃描儀與服務兩項收入增加,進而帶來營業費用的槓桿效益。關於我們第四季的所得稅提列,我們的稅率為92.4%,較去年同期同一季的19.8%上升72.6個百分點,其中包含因2017年12月22日頒布的美國《減稅與就業法案》所產生的8,660萬美元稅費。其中包括7,660萬美元的強制性視同匯回稅,係針對先前未在美國課稅之累積海外盈餘(外國—對累積海外盈餘)所課徵,我們預期將在未來8年內繳納;以及因法定稅率由35%降至21%而對遞延所得稅資產進行的1,000萬美元非現金減記。展望未來,我們可能將現金匯回美國,以投資市場擴張機會、提供額外營運資金,並提高資金運用彈性以支應我們的股票回購計畫。依據SEC員工會計公告第118號,我們已在第四季財務報表中,針對該法案若干所得稅影響,基於合理估計及期末可得資訊,認列暫估金額。在未來一年內,隨著取得更多資訊、分析及立法指引,我們可能會調整並精煉該等暫估金額。
Fourth quarter diluted earnings per share was $0.13, down 87.1% sequentially and down 78% compared to the prior year. Our diluted earnings per share includes $86.6 million or $1.06 per diluted share impact due to the new U.S. Tax Cuts and Jobs Act. Moving on to the balance sheet. As of the fourth quarter, cash, cash equivalent and marketable securities, including both short and long-term investments, were $761.5 million. This compared to $700 million at the end of 2016, an increase of approximately $61.5 million, primarily related to earnings growth. Of our $761.5 million of cash, cash equivalent and marketable securities, $271.4 million was held by the U.S. and $490.1 million was held by our international entities. Q4 accounts receivable balance was $322.8 million, up approximately 0.5% sequentially. Our overall day sales outstanding, DSO, was 69 days, down 6 days sequentially and down 7 days from 76 days in Q4 last year. DSOs have decreased as a result of improved collection activities across all regions. Cash flow from operations for the fourth quarter was $162.3 million, up $81.3 million compared to prior year. Free cash flow for the fourth quarter, defined as cash flow from operations, less capital expenditures, amounted to $92.8 million. Capital expenditures for the fourth quarter were $69.5 million, primarily relating to building purchases and improvements, equipment purchases for additional manufacturing capacity as well as our global expansion efforts, including a new manufacturing facility in [Zhong], China, which will open in the second half of 2018.
第四季稀釋後每股盈餘為0.13美元,較前一季下滑87.1%,較去年同期下滑78%。我們的稀釋後每股盈餘包含因新的美國《減稅與就業法案》所造成的8,660萬美元(或每股稀釋後1.06美元)影響。接著看資產負債表。截至第四季,現金、約當現金及有價證券(含短期與長期投資)為7.615億美元。相較於2016年底的7.00億美元,增加約6,150萬美元,主要與獲利成長相關。在7.615億美元的現金、約當現金及有價證券中,2.714億美元由美國持有,4.901億美元由我們的國際實體持有。第四季應收帳款餘額為3.228億美元,較前一季約增加0.5%。整體應收帳款週轉天數(DSO)為69天,較前一季減少6天,亦較去年第四季的76天下降7天。DSO下降係因各區域收款活動改善所致。第四季營運活動現金流量為1.623億美元,較去年同期增加8,130萬美元。第四季自由現金流量(定義為營運活動現金流量減資本支出)為9,280萬美元。第四季資本支出為6,950萬美元,主要用於購置與改善建物、為增加製造產能而購置設備,以及我們的全球擴張計畫,包括位於中國[Zhong]的新製造設施,預計於2018年下半年啟用。
During the fourth quarter, we repurchased approximately 0.2 million shares of stock for $50 million under the April 2016 repurchase program. We have $200 million remaining available for repurchases under the existing stock repurchase authorization.
第四季期間,我們依據2016年4月的回購計畫,以5,000萬美元回購約20萬股股票。在現行股票回購授權下,我們尚有2.00億美元可用於回購。
Before we move to the Q1 outlook, I would like to make a few comments on our full year 2017 results. In 2017, we shipped a record 931,000 Invisalign cases, up 31.4%. This reflects 44.9% volume growth from our international doctors and 24.3% volume growth from our North American doctors. Shipments of our iTero scanners were up 37.5% over 2016. Total revenue was a record $1.5 billion, up 36.4% year-over-year, with Invisalign revenues breaking above $1 billion for the first time. Full year operating income of $353.6 million, up 42.1% versus 2016 and operating margin at 24%, up 0.9 points versus prior year. Free cash flow was $242.8 million. For the year, we repurchased 0.6 million shares of Align stock for $103.8 million. 2017 diluted earnings per share was $2.83, which includes $86.6 million or $1.06 per diluted share impact due to the new U.S. Tax Cut and Jobs Act comprised of a $10 million write-down of our deferred tax assets and a mandatory deem repatriation tax of $76.6 million. With that, let's turn to our Q1 outlook and the factors that inform our view, starting with the demand outlook. We expect our international business to continue to grow sequentially. For North America, we expect Q1 to be seasonally up for both GP dentists and orthos. For our Scanner business, we expect a sequential decrease following a strong year-end. In addition, capital equipment purchases are seasonally slower in Q1. As Joe commented earlier, this quarter, we supplied fewer aligners to SDC in Q4 2017 compared to prior quarters. We are anticipating this trend to continue as SDC continues to ramp up their own manufacturing capacity. With this as a backdrop, we expect the first quarter to shape up as follows: Invisalign case volume is expected to be in the range of 264,000 to 269,000 cases, up approximately 27% to 29% over the same period a year ago. We expect Q1 net revenues to be in the range of $400 million to $410 million, an increase of approximately 29% to 32% year-over-year. We expect Q1 gross margin to be in the range of 74.3% to 75%, reflecting higher expenses as we regionalize our treatment planning operations, partially offset by higher ASPs. We expect Q1 operating expenses to be in the range of $223.5 million to $227.5 million, up on a sequential basis to reflect our continued investment in go-to-market activities. Q1 operating margins should be in the range of 18.5% to 19.5%. Our effective tax rate, including an excess tax benefit of about $22 million, should be approximately 2%. We expect a $1 million to $2 million loss related to our share of SmileDirectClub. And diluted shares outstanding should be approximately 82 million, exclusive of any share repurchases. Taken together, we expect our Q1 diluted earnings per share to be in the range of $0.94 to $0.98. In addition, as we continue our operational expansion efforts, we expect capital expenditures for Q1 to be approximately $65 million to (inaudible), and we expect depreciation and amortization to be $10.5 million to $11 million.
在我們進入第一季展望之前,我想先就2017年全年業績做幾點說明。2017年,我們出貨創紀錄的931,000例Invisalign病例,成長31.4%。這反映國際醫師出貨量成長44.9%,以及北美醫師出貨量成長24.3%。我們的iTero掃描儀出貨量較2016年成長37.5%。總營收創紀錄達15億美元,年增36.4%,其中Invisalign營收首次突破10億美元。全年營業利益為3.536億美元,較2016年成長42.1%,營業利益率為24%,較前一年提高0.9個百分點。自由現金流量為2.428億美元。全年我們以1.038億美元回購60萬股Align股票。2017年稀釋後每股盈餘為2.83美元,其中包含因新的美國《減稅與就業法案》所造成的8,660萬美元(或每股稀釋後1.06美元)影響,該影響由1,000萬美元的遞延所得稅資產減記,以及7,660萬美元的強制性視同匯回稅所構成。接下來讓我們轉到第一季展望,以及支撐我們看法的因素,先從需求展望開始。我們預期國際業務將持續呈現季對季成長。就北美而言,我們預期第一季在一般牙醫(GP)與矯正科醫師(ortho)兩方面皆有季節性成長。就掃描儀業務而言,在年末表現強勁之後,我們預期將出現季對季下滑。此外,資本設備採購在第一季通常較為疲弱,具季節性。如Joe先前所述,本季我們在2017年第四季供應給SDC的牙套數量較前幾季更少。隨著SDC持續擴增其自有製造產能,我們預期此趨勢將延續。在此背景下,我們預期第一季表現如下:Invisalign病例量預計介於264,000至269,000例,較去年同期約成長27%至29%。我們預期第一季淨營收介於4.00億至4.10億美元,年增約29%至32%。我們預期第一季毛利率介於74.3%至75%,反映我們將治療規劃作業區域化所帶來的較高費用,部分由較高的平均售價(ASP)所抵銷。我們預期第一季營業費用介於2.235億至2.275億美元,季對季上升,以反映我們持續投資於市場推廣(go-to-market)活動。第一季營業利益率應介於18.5%至19.5%。我們的有效稅率(包含約2,200萬美元的超額稅務利益)應約為2%。我們預期與我們持有SmileDirectClub權益相關的損失為100萬至200萬美元。稀釋後流通在外股數約為8,200萬股,不含任何股票回購。綜合以上,我們預期第一季稀釋後每股盈餘介於0.94至0.98美元。此外,隨著我們持續推動營運擴張,我們預期第一季資本支出約為6,500萬美元至(聽不清),並預期折舊與攤銷為1,050萬至1,100萬美元。
Now let me turn to our full year view. We anticipate 2018 revenue to be at the high end of our long-term operating model range of 15% to 25%. We also expect Invisalign revenue and volume growth to be close to the high end of that model. While we expect the Scanner business to do well and continue to grow, we would not expect the same rate of growth of volume and revenue as we saw in 2017. We expect operating margins to be approximately flat to 2017 result as we plan to continue to fund our investments to fuel growth. We expect the equity loss for our investment in SmileDirectClub to be $1 million to $2 million per quarter. We expect our tax rate for 2018 to be approximately 18%, which includes approximately $24 million of excess tax benefits. As we've seen historically, we expect our earnings power in the second half of the year to be stronger than the first half, with second half operating income to account for somewhere in the range of 56% to 58% of our full year results. We expect capital expenditures for 2018 to be in the range of $200 million to $230 million, primarily due to operational expansion and ongoing growth of the business.
現在讓我轉到我們對全年展望的看法。我們預期2018年營收將落在我們長期營運模型15%至25%區間的高端。我們也預期Invisalign營收與出貨量成長將接近該模型的高端。雖然我們預期掃描器業務表現良好並持續成長,但我們不預期其出貨量與營收能維持2017年所見的同等成長速度。由於我們計畫持續投入資金以支持成長,我們預期營業利益率將大致持平於2017年的結果。我們預期對SmileDirectClub投資所產生的權益法損失每季為100萬至200萬美元。我們預期2018年的稅率約為18%,其中包含約2,400萬美元的超額稅務利益。如同過往歷史所示,我們預期下半年獲利能力將強於上半年,下半年營業利益約占全年結果的56%至58%。我們預期2018年資本支出將介於2億至2.3億美元之間,主要由於營運擴張以及業務持續成長。
Finally, regarding the new revenue recognition standard, ASC 606, we plan to adopt the standard in the first quarter of 2018 by applying the full retrospective method. We have assessed the financial statement impact of adoption, including but not limited to, volume-based discount programs, sales commissions and the identification of performance obligations, and are continuing to evaluate the transition and disclosure requirements of the standard. We anticipate the adoption of the standard will not have a material impact to our consolidated financial statements. With that, I'll turn it back over to Joe for final comments. Joe?
最後,關於新的收入認列準則ASC 606,我們計畫於2018年第一季採用該準則,並採用完全追溯法。我們已評估採用後對財務報表的影響,包括但不限於按出貨量計算的折扣方案、銷售佣金以及履約義務的辨識,並持續評估該準則的轉換與揭露要求。我們預期採用該準則不會對我們的合併財務報表造成重大影響。接下來我把時間交回Joe做最後評論。Joe?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Thanks, John, and thanks again for joining us. 2017 was a great year for Align, and I'm very pleased with our strong performance across all key regions, customer channels and product lines. This year, not only did we celebrate our 20th year in business, we also achieved several major milestones. We reached our millionth Invisalign Teen and our 5 millionth Invisalign patient. Invisalign volume in EMEA exceeded 200,000 cases for the first time. We opened our first treatment planning operations in China and Germany. China became our second largest country market next to the U.S. Invisalign revenues exceeded $1 billion for the first time ever.
謝謝你,John,也再次感謝各位加入我們。2017年對Align而言是非常出色的一年,我對我們在所有主要地區、客戶通路與產品線的強勁表現感到非常滿意。今年,我們不僅慶祝公司成立第20週年,也達成了數個重要里程碑。我們達成第100萬位Invisalign Teen患者,以及第500萬位Invisalign患者。EMEA地區的Invisalign出貨量首次超過20萬例。我們在中國與德國開設了第一個治療規劃營運據點。中國成為僅次於美國的第二大國家市場,Invisalign營收也首次突破10億美元。
As I reflect on these achievements, I want to take a minute to thank more than 130,000 Invisalign providers around the world who helped us expand the market for orthodontics using the Invisalign system. Their increasing confidence in using Invisalign clear aligners to treat moderate to complex cases is reflected in our record utilization across all customer channels, and we're grateful for their partnership. We are continuing innovating to deliver new technology and solutions that provide Invisalign doctors with the right tools, support and services to keep their practices flourishing.
回顧這些成就,我想花一點時間感謝全球超過13萬名Invisalign供應者,協助我們使用Invisalign系統擴大齒顎矯正市場。他們對使用Invisalign透明牙套治療中度至複雜病例的信心日益提升,反映在我們於所有客戶通路創下的使用率紀錄上,我們也感謝他們的合作夥伴關係。我們將持續創新,提供新技術與解決方案,為Invisalign醫師提供合適的工具、支援與服務,協助其診所持續蓬勃發展。
Even with growth rates significantly above the industry, our market opportunity is enormous and getting larger every day. With less than 10% share of the world orthodontic case starts each year, we have a long way to go to make clear aligners the standard of care, but our goal is to do just that. There are more than 300 million people around the world who would or could benefit from straighter teeth. Reaching out to those consumers, helping them understand treatment options and getting them started in treatment will require new approaches and new models. We're committed to doing that in partnership with our customers. For 2018, we'll continue to focus on and execute our 4 key strategic priorities, and I feel really good about our plans. We're continuing to expand our business in EMEA, APAC and will accelerate investment in LatAm and Canada, bringing more resources closer to our customers and launching direct-to-consumer advertising in some markets like Canada for the first time.
即使成長率顯著高於產業水準,我們的市場機會仍然非常龐大,且每天都在擴大。全球每年開始的齒顎矯正病例中,我們的市占率仍低於10%,要讓透明牙套成為標準治療方式仍有很長的路要走,但這正是我們的目標。全球有超過3億人可能或可以從更整齊的牙齒中受益。要觸及這些消費者、協助他們了解治療選項並讓他們開始治療,將需要新的方法與新的模式。我們承諾將與客戶合作共同完成。在2018年,我們將持續聚焦並執行四項關鍵策略優先事項,我對我們的計畫非常有信心。我們將持續擴展在EMEA與APAC的業務,並加速在拉丁美洲與加拿大的投資,把更多資源帶到更貼近客戶的地方,並首次在加拿大等部分市場推出面向消費者的直接廣告。
The teenage market remains our #1 priority across the ortho channel, and for the first time, we will focus on teens and their moms in our consumer marketing programs in the EMEA region, making it easier for GP dentists to treat more cases, also enables them to refer more complex ones to specialists. So we are creating dedicated GP resources across our sales and marketing organizations to ensure that we have a better understanding of how to drive Invisalign adoption among GP dentists and support their unique customer needs, including restorative and aesthetic dentistry.
青少年市場仍是我們在矯正通路中的第一優先事項;而且我們將首次在EMEA地區的消費者行銷計畫中聚焦青少年及其母親,讓一般牙醫(GP)更容易治療更多病例,同時也使他們能將更複雜的病例轉介給專科醫師。因此,我們正在銷售與行銷組織中建立專屬的GP資源,以確保我們能更了解如何推動GP牙醫採用Invisalign,並支援其獨特的客戶需求,包括修復與美學牙科。
And finally, the Invisalign brand and our consumer marketing programs are key differentiators for the company. So we'll continue to invest and to build capabilities that enable us to talk directly to consumers, improve the overall experience with our brand, connect more people than ever with Invisalign practices and ensure that they get started in a treatment with Invisalign clear aligners every time.
最後,Invisalign品牌以及我們的消費者行銷計畫是公司的關鍵差異化因素。因此,我們將持續投資並建立能力,使我們能直接與消費者溝通、提升整體品牌體驗、讓比以往更多的人與Invisalign診所建立連結,並確保他們每次都能以Invisalign透明牙套開始治療。
With that, I'll turn it over to the operator, and we'll open the call up for your questions. Operator?
接下來我把時間交給接線員,我們將開放電話會議讓各位提問。接線員?
Operator
Operator
(Operator Instructions) Our first question is with Robert Jones with Goldman Sachs.
(接線員指示) 我們的第一個問題來自高盛的Robert Jones。
Nathan Allen Rich - Research Analyst
Nathan Allen Rich - Research Analyst
This is Nathan Rich on for Bob this evening. Joe, I just wanted to start with the revenue outlook for growth to be at the high end of the long-term range. Obviously, that still implies a healthy level of growth but down a little bit from what you guys saw in 2017. You spent a lot of time on the call, obviously, talking about the initiatives that you've put in place and the opportunity that the company still has. So I was just wondering if you could maybe help us understand what the key drivers of the outlook are for this year and what, if anything, has changed from your point of view.
今晚由Nathan Rich代替Bob發言。Joe,我想先從營收展望談起,你們預期成長將落在長期區間的高端。顯然,這仍意味著健康的成長水準,但比起你們在2017年看到的略低一些。你們在電話會議中花了很多時間談到已推動的各項措施,以及公司仍擁有的機會。因此我想請你協助我們了解今年展望的關鍵驅動因素是什麼,以及從你的角度看,有哪些(如果有的話)已經改變。
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Well, I think nothing has really changed in that sense. Obviously, there's some amplitude that we're talking about in a sense of what we're calling right now. But overall, we see good momentum in the business. And what we're trying to convey with you is to stay within the volume ranges that we've talked about before. But we're just going to look quarter-to-quarter. We continue to look at the same drivers, I mean, continue to look at APAC being strong. Europe will be strong in North America, particularly around teens, and our focus there is iTero scanners continue to go off well. So overall, I feel -- I really feel good about our forecast, and we'll be more and more clear, obviously, as we come back to you after the first quarter.
嗯,我認為從這個意義上來說其實沒有什麼真正改變。當然,就我們目前所提出的指引而言,某種程度上存在一些波動幅度。但整體而言,我們看到業務動能良好。我們想傳達的是,我們仍會維持在先前談過的出貨量區間內。不過我們會逐季觀察。我們持續關注相同的驅動因素,也就是APAC依然強勁。歐洲與北美也會強勁,北美特別是在青少年方面;而我們在那裡的重點是iTero掃描器持續有很好的表現。因此整體而言,我對我們的預測感覺非常好;而且在第一季之後再回來與各位更新時,我們也會更清楚地說明。
Nathan Allen Rich - Research Analyst
Nathan Allen Rich - Research Analyst
Okay. And just a follow-up on the outlook. Does it contemplate any change in the competitive landscape in 2018? And if you were to see a new competitor come to market, how would that impact your view of the year?
好的。另外再追問一下關於展望。這是否已納入對 2018 年競爭態勢的任何變化?如果你們看到有新的競爭者進入市場,這會如何影響你們對今年的看法?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
I think, Nathan, we've been very, I think, clear over the last year or so that we do expect competition in 2018. In these forecasts, we are reflecting any kind of competition we might see. But there's been nothing out there recently that's changed any position that we've had from a competitive standpoint. So these forecasts do reflect how we see the marketplace, and that includes potential competition as we get into longer parts of this year.
Nathan,我想我們在過去一年左右已經非常、我想也很清楚地表示,我們確實預期 2018 年會有競爭。在這些預測中,我們已反映我們可能看到的各種競爭情況。但最近並沒有任何事情,從競爭角度來看,改變我們既有的立場。因此,這些預測確實反映了我們對市場的看法,其中也包含在今年較後段可能出現的潛在競爭。
Operator
Operator
Our next question is with Erin Wright with Crédit Suisse.
下一個問題來自瑞士信貸(Crédit Suisse)的 Erin Wright。
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Can you speak to your retail store concept and how you envision that progressing and how -- has there been any sort of surprises thus far with the initiative? And how will the Smile Concierge team be involved? Like do you plan to leverage your Smile Concierge build out another country as well to then leverage a retail store concept there? Or is it too early on that front?
你能談談你們的零售門市概念,以及你們如何設想它的推進與發展嗎?到目前為止,這項計畫是否有任何意外或驚喜?另外,Smile Concierge 團隊將如何參與?例如,你們是否也計畫把 Smile Concierge 的建置擴展到其他國家,並在那裡也導入零售門市概念來加以運用?還是說在這方面現在談還太早?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Well, we are translating, Erin, the Smile Concierge program overseas. We'll look at it. We'll move it into APAC this year and also move it into EMEA. What's nice about it is scalable right now. We can take what we've learned in North America, and there's a lot of IT involved and a lot of process in a sense of how you turn a consumer into patients that we're able to, I think, plug-and-play much better now because we have that experience. That's really what -- that understanding is what led to the Invisalign store, the pilot that we currently have in San Francisco. Just wanted to move this even closer to patients. And remember, again, we're not doing any kind of diagnosis or anything like that. We do scans in these shops, and we show potential patients or consumers what their smiles could look like in 2 different sets of -- 2 different approaches, what we call Signature and Deluxe. I would say, what we're doing, we continue to -- it is a pilot. We work through the workflow between us and the doctor and us and the patient, and we refine that pretty well over the last 60 days and we're making progress. That will give us the confidence to announce that we're going to move a store in the San Jose and also 2 on the East Coast this year. But we'll be very clear with you about what we learn. But again, this is all about how you turn a consumer into a patient. And this is as much -- this is a doctor model. I mean, we're working with our doctors to make this happen. And so how you touch these consumers, how the frictionless way that you move a consumer into a doctor, how fast that information can be received, all that is really important in this customer journey, and we're learning more and more about that and how to do it better. So we're optimistic about it, and we do have this in our future plans. And obviously, just like the concierge services, we have success here and we have a model we think is scalable. We'll look at where that might fit in different countries around the world.
Erin,我們正在把 Smile Concierge 計畫推向海外。我們會評估它。今年我們會把它推進到亞太(APAC),也會推進到歐洲、中東與非洲(EMEA)。好處是它目前具備可擴展性。我們可以把在北美學到的經驗帶過去,其中牽涉很多 IT,也有很多流程——某種意義上是如何把消費者轉化為病患——因為有了這些經驗,我想我們現在能更好地以「即插即用」的方式複製。也正是這樣的理解,促成了 Invisalign 門市,也就是我們目前在舊金山的試點。我們只是想把服務再更貼近病患一些。而且再提醒一次,我們不做任何診斷或類似的事情。我們在這些店裡做掃描,並向潛在病患或消費者展示他們的笑容在兩種不同方案下可能呈現的樣子——我們稱之為 Signature 與 Deluxe。我會說,我們正在做的事情仍在持續——這是一個試點。我們在我們與醫師之間、以及我們與病患之間的工作流程上持續磨合,過去 60 天我們已經把它優化得相當不錯,並且正在取得進展。這將讓我們有信心宣布今年會在聖荷西再開一家門市,並且在美國東岸再開兩家。不過,我們會很清楚地向各位說明我們學到了什麼。但再次強調,這一切都是關於如何把消費者轉化為病患。而且這同樣——這是一個以醫師為核心的模式。我的意思是,我們正與我們的醫師合作來促成這件事。因此,如何接觸這些消費者、如何以無摩擦的方式把消費者導向醫師、資訊能多快被接收——這些在客戶旅程中都非常重要;我們也在這方面學到越來越多,並且學著如何做得更好。所以我們對此感到樂觀,而且這確實在我們未來的規劃之中。而且顯然,就像禮賓服務一樣,我們在這裡取得成功,也有一個我們認為可擴展的模式。我們會評估它在全球不同國家可能適用的地方。
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
Erin Elizabeth Wilson Wright - Director & Senior Equity Research Analyst
And can you give us an update on the mandibular advancement here? What sort of data has been requested from the FDA? And what sort of visibility do you have on timing of the launch? I guess, what are the next data points there and also how traction for that product, I guess, is helping to build adoption across the teen market outside of the U.S.?
另外,你能更新一下下顎前移(mandibular advancement)的進展嗎?FDA 要求提供哪些類型的資料?你們對上市時程的能見度如何?我想問的是,接下來有哪些關鍵資料點?以及我猜,這個產品的推進力是否也有助於在美國以外的青少年市場提升採用率?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Erin, this is really -- this is actually simple. It's not like a drug or anything like that. They just need more data at the FDA, and they just want to have more comfort with the safety and the efficacy of the product line. So we're supplying that data. We expect -- hopefully, we'll be through that by the second half of this year, and then we'll move on. I mean, we -- I talked about the 5,000 cases that we did last year, with 2,500 of those being in the fourth quarter alone. Honestly, the feedback that we get from our patients overseas is tremendous. I mean, when we look at the device that we've replaced through this, it's amazing, like a twin block device that's normally used out there. When you can actually move this jaw forward as comfortably as we do with MAF but also straighten teens' teeth at the same time, it's really an amazing invention. So I think that's part of the way the FDA wants more and more information because they really haven't seen a device like this before. But we feel very confident we'll be able to supply their informational needs. And as we move in the second half of this year, we'll give you more clarity on exactly where that stands.
Erin,這其實——其實很簡單。它不像藥物或類似的東西。FDA 只是需要更多資料,他們只是希望對這條產品線的安全性與有效性更有把握。所以我們正在提供那些資料。我們預期——希望能在今年下半年完成這個流程,然後再往下推進。我的意思是——我提過我們去年做了 5,000 個案例,其中光第四季就有 2,500 個。老實說,我們從海外病患那裡得到的回饋非常好。當我們看這項產品所取代的裝置時,真的很驚人,例如海外通常使用的 twin block 裝置。當你能像我們用 MAF 那樣舒適地把下顎往前移,同時又能把青少年的牙齒矯正整齊,這真的是一項很了不起的發明。所以我想這也是 FDA 想要更多資訊的原因之一,因為他們以前真的沒看過這樣的裝置。但我們非常有信心能滿足他們對資訊的需求。而隨著我們進入今年下半年,我們會就目前進度提供各位更明確的說明。
Operator
Operator
Our next question is with Richard Newitter with Leerink Partners.
下一個問題來自 Leerink Partners 的 Richard Newitter。
Jaime Lynn Morgan - Associate
Jaime Lynn Morgan - Associate
This is Jaime on for Rich Newitter. A quick question I have, I guess, is on the teen segment. Of course, you guys posted nice performance this quarter. So I'm kind of thinking about when you guys think this market could be potentially reaching an inflection point and how we should be thinking about the additional investments in your direct-to-consumer campaign and really seeing the payoff there and how it translates into further growth in 2018.
我是 Jaime,代 Rich Newitter 提問。我有個簡短問題,主要是關於青少年(teen)族群。當然,你們本季表現不錯。所以我在想,你們認為這個市場可能何時會到達拐點?以及我們應該如何看待你們在直面消費者(direct-to-consumer)行銷活動上的額外投資、何時能真正看到回報,以及它如何轉化為 2018 年的進一步成長?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Jaime, it's Joe again. Look, I would say we've done one and a row on teens, and we have more work to do on this. But we have to put a lot of money into this system in a sense of educating moms and teens, peer-to-peer training for doctors, all these things. And so I'd say the whole idea or enthusiasm around a tipping point, we're not there yet. We have to continue to see this market and push this market in order to get it going. We're confident in our ability to do that based on what we've experienced the last 5 quarters but not necessarily ready to do to claim victory. And this has its own momentum at this point in time.
Jaime,我是 Joe。你看,我會說我們在青少年市場已經連續取得一些成果,但在這方面還有更多工作要做。不過我們必須在這個系統上投入大量資金,某種意義上是教育媽媽與青少年、為醫師提供同儕對同儕的培訓,還有所有這些事情。所以我會說,關於所謂的拐點或臨界點的想法或熱情,我們還沒到那一步。我們必須持續觀察並推動這個市場,才能讓它真正運轉起來。基於過去 5 個季度的經驗,我們對自己推動市場的能力有信心,但還不到可以宣告勝利的程度。而且就目前而言,這件事已經開始形成它自己的動能。
Jaime Lynn Morgan - Associate
Jaime Lynn Morgan - Associate
Okay, great. And then just one other quick question on scanners. I guess, you were saying for your -- if I heard you correctly, for the full year 2018, you're not expecting the same sort of growth for the scanner business. So just kind of on that front, what sorts of expectations or assumptions do you have that baked in for 2018 for growth in this market?
好的,很棒。然後關於掃描器我還有一個很快的問題。我想,你剛才說的是——如果我沒聽錯的話,對於2018年全年,你們不預期掃描器業務會有同樣類型的成長。所以在這方面,你們對2018年這個市場的成長,內部已經納入了哪些預期或假設?
John F. Morici - CFO
John F. Morici - CFO
Jaime, this is John. We would expect scanner growth to be approximately equal to Invisalign.
Jaime,我是John。我們預期掃描器的成長大約會與Invisalign相當。
Operator
Operator
Our next question is with Jon Block with Stifel.
下一個問題來自Stifel的Jon Block。
Jonathan D. Block - MD and Analyst
Jonathan D. Block - MD and Analyst
Joe, maybe for you. In 2018, another great year of revenue growth expectations and another year of sort of healthy spend expectations as well, so maybe if you can talk to where that spend is being allocated. Clearly, there's a return, but what is it? Is it more reps? Is it additional DTC? Is it both? And then how do we think about that spend maybe throughout the year in terms of reaching for that critical mass on the rep front? And then I've got a follow-up.
Joe,可能這題給你。2018年又是一個營收成長預期很強的一年,同時也預期會有另一年相對健康的支出,所以也許你可以談談這些支出會配置到哪裡。顯然是有回報的,但回報是什麼?是更多業務代表嗎?是增加更多DTC(直接面向消費者)嗎?還是兩者都有?另外,從全年節奏來看,我們該如何看待這些支出,特別是在業務代表端要達到臨界規模(critical mass)方面?然後我還有一個追問。
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
John, what we're doing, we're basically magnifying the investments that we made in 2017. So you'll see, again, investments in teen, broader advertisements that we know helped to drive GP volume growth, particularly in the United States, too, investments in our concierge service. But behind that, too, is what you alluded to also is more field people on the ground calling on customers to actually drive the business. So there's a direct -- when you look at the correlation between our investment in these particular areas to drive demand and the demand we're able to drive, and we can see that we realized through that, we're just continuing on the same plan that we have before, Jon. Behind you, I know your question is leverage, exactly when that leverage does occur. I mean, that's -- obviously, I'm not avoiding that. It's just -- I don't -- this thing is not self-sustaining yet. We have to invest in to drive demand in this business and to educate consumers and particularly and to train doctors. And so I don't see that going away in 2018, Jon.
John,我們在做的事情,基本上是把2017年的投資再放大。所以你會再次看到對青少年市場的投資、更廣泛的廣告投放——我們知道這些有助於推動GP(一般牙醫)病例量成長,尤其是在美國——也會投資我們的禮賓(concierge)服務。但在這背後,如你所提到的,還包括增加更多前線人員在市場上拜訪客戶,實際推動業務。所以當你看我們在這些特定領域的投資與我們能夠帶動的需求之間的相關性時,你會看到這是直接的——我們能看見我們因此而實現的成果;我們只是延續之前的同一個計畫,Jon。我知道你問題背後是在問槓桿(leverage),也就是那個槓桿到底何時會出現。我的意思是——很明顯,我不是在迴避這個。只是——我不——這個業務目前還不是自我維持(self-sustaining)的狀態。我們必須投入資源來帶動需求、教育消費者,尤其是培訓醫師。因此我不認為2018年這些投入會消失,Jon。
Jonathan D. Block - MD and Analyst
Jonathan D. Block - MD and Analyst
I was going to give you a pass, Joe, on the leverage with the top line and where it is. But to shift gears, I know it's early, but I do want to sort of follow up on the storefront initiative. Clearly, the model, it gets the volume into the docs' offices and you've been very vocal about that and it's unlike that of SDC, but what are you hearing from your customers, maybe even if it's only specific in San Francisco? Are there any that are sort of unsettled by, call it, the fixed economics for express type cases? They should be saying, "Hey, I'm getting $500 instead of $50 for doing an SDC mockup." But have they come around? Or what are you hearing in the early days from that customer base?
Joe,關於營收端的槓桿以及它在哪裡,我本來打算先放你一馬。但換個話題,我知道現在還早,不過我確實想追問一下你們的門市(storefront)計畫。很明顯,這個模式會把量導入醫師診所,你們也一直很直白地談到這點,而且它不同於SDC,但你們從客戶那邊聽到什麼回饋?即便只限於舊金山也可以。有沒有一些醫師對於所謂快速(express)類型病例的固定經濟條件(fixed economics)感到不安?他們理應會說:「嘿,我做一個SDC的模擬(mockup)能拿到500美元,而不是50美元。」但他們是否已經接受了?或者在早期階段,你們從那個客戶群聽到的是什麼?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Jon, from a San Francisco store standpoint, when you ask the doctors around San Francisco about the store, there's enthusiastic support for it because they're close to it and they see what we're doing. But if you go around the country, there is anxiety with doctors in a sense of what is Align trying to do with these stores and how to go about it. So we continue to try to communicate that this is a doctor's model, and we're trying to drive that demand as much as we can through the orthodontist and also the GP. There's a specific question about the Signature product and our cost for it. I mean, that hasn't been a favorite of our doctors that we set that price, but obviously, there is a market price for around that, for that kind of, and I call it anterior teeth movement, which is basically just a smile kind of improvement that we know that patients really want and we feel that we have to deliver. There are some docs that readily support it and are happy with it. There's other ones that aren't happy with it, too. And we continue to let them make that selection, whether they want to participate in that or not. We also have our Deluxe cases as we haven't set a price on, that the orthodontists have been very happy with in a sense that we do have a significant number of patients that offer the Deluxe, too, when they understand potential bite changes and what that might do for the long-term dentition. Hope that helps, Jon.
Jon,從舊金山門市的角度來看,當你問舊金山周邊的醫師對門市的看法時,他們是熱情支持的,因為他們離得近,也看得到我們在做什麼。但如果你走訪全國,醫師會有焦慮感,某種程度上是在想Align想透過這些門市做什麼、以及要怎麼做。所以我們持續溝通:這是一個以醫師為核心的模式,我們希望盡可能透過矯正專科醫師以及GP來帶動需求。你有一個具體問題是關於Signature產品以及我們對它的定價。我的意思是,醫師並不特別喜歡我們設定那個價格,但很顯然,市場上對那一類——我稱之為前牙移動(anterior teeth movement),基本上就是改善笑容——是有一個市場價格的;我們知道病患非常想要這種改善,我們也覺得必須提供。有些醫師很樂意支持,也對此感到滿意。也有一些醫師不滿意。我們會繼續讓他們自行選擇是否要參與。另外,我們也有Deluxe病例,我們沒有對其設定價格;矯正專科醫師對此非常滿意,因為當他們理解潛在咬合改變以及這對長期齒列可能造成的影響時,我們確實有相當多的病患也會選擇Deluxe。希望這能幫到你,Jon。
Operator
Operator
Our next question is with Steve Beuchaw with Morgan Stanley.
下一個問題來自Morgan Stanley的Steve Beuchaw。
Zachary Ryan Wachter - Research Associate
Zachary Ryan Wachter - Research Associate
This is actually Zach Wachter on for Steve. Joe, I wonder if you saw the 3Shape and 3M release out today on the collaboration. And any early thoughts on that?
其實我是代Steve提問的Zach Wachter。Joe,我想問你今天是否看到3Shape和3M針對合作所發布的消息。你對此有沒有任何初步想法?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Yes. Zach, the one thing I was kind of stunned with was that, basically, 3M admitted that their scanner doesn't function properly for digital marketplace. I mean, that surprised me more than anything. With that, it doesn't surprise me that they would go to 3Shape because 3Shape does have a good confocal imaging scanner, as we know, partially supported by our technology. But that's just to be expected in that sense. But I -- the real part that surprised me was really the desk scanner that 3M currently has apparently will be retired in some way. So as far as what does that mean from a competitive standpoint, it doesn't change anything at all. It just means that 3M felt that they needed a different front-end from a digital standpoint in their system than what they currently manufacture.
有。Zach,我有點震驚的一點是,基本上3M承認他們的掃描器在數位市場(digital marketplace)上無法正常運作。我的意思是,這比任何事情都更讓我意外。在這種情況下,他們轉向3Shape並不令人意外,因為我們知道3Shape確實有一個不錯的共焦成像(confocal imaging)掃描器,且部分由我們的技術所支援。所以從這個角度來看,這是意料之中的。但我——真正讓我驚訝的是,3M目前的桌上型掃描器(desk scanner)顯然會以某種方式被淘汰。所以就競爭層面而言,這完全不會改變任何事情。這只代表3M覺得他們在系統的數位前端(front-end)需要一個不同於目前自家製造的方案。
Zachary Ryan Wachter - Research Associate
Zachary Ryan Wachter - Research Associate
Okay, great. And as far as the 3Shape transition on the scan submissions, how are you doing in terms of backfilling those volumes? And what do you think about the overall impact there?
好的,很棒。那關於3Shape在掃描提交(scan submissions)上的轉換,你們在回補(backfilling)那些量方面做得如何?你怎麼看整體影響?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
That's like we didn't call in our forecast any impact. We have customers upset at us because we had to make that move and wanted to make that move. But we're working through that, through offers of iTero that helped to offset this and also through subsidizing some submissions that we could have in a fundamental way than the analog way in order to do impressions. So right now, we're not calling any kind of a downside based on that. We emphasize with customers that have been affected from a workflow standpoint. We're doing everything we can to mitigate that and make it as easy as possible.
就像我們在預測中並沒有提到任何影響一樣。有些客戶對我們不滿,因為我們必須做出那個轉換,而且也想做出那個轉換。但我們正在處理這件事:透過提供iTero的方案來幫助抵消影響,也透過補貼部分提交,讓他們能以更根本的數位方式,而不是用傳統(analog)的方式來做印模。所以目前我們不認列任何形式的下行影響(downside)。我們同理那些在工作流程(workflow)上受到影響的客戶。我們正在盡一切努力降低影響,並讓流程盡可能容易。
Zachary Ryan Wachter - Research Associate
Zachary Ryan Wachter - Research Associate
Okay. And there have been a couple of questions on the storefront. I wonder specifically on the consumer finance program separate from the store, if there have been any early learnings there that you can share and any incremental volume lift to speak to.
好的。而且在門市端也有幾個問題。我想特別針對獨立於門市之外的消費者金融方案,是否有任何早期學習可以分享,以及是否有任何可談的額外量能提升?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Zach, these are good questions. We got to tell Steve -- we'll tell Steve how good you are. We're going to -- John is going to answer that question for you.
Zach,這些問題問得很好。我們得告訴 Steve——我們會告訴 Steve 你有多厲害。我們會——John 會替你回答這個問題。
John F. Morici - CFO
John F. Morici - CFO
Zach, it's John. Look, we're doing a pilot now in some key markets and learning a lot and working through to make sure that we have the best possible patient and customer experience through this. So we're learning, making sure that it gets rolled out in the right way. And you'll see a larger rollout coming in the future.
Zach,我是 John。你看,我們目前正在一些關鍵市場做試點,學到很多,也在持續推進,確保透過這個方案能提供最佳的病患與客戶體驗。所以我們一邊學習,一邊確保以正確的方式推出。未來你會看到更大規模的推廣。
Operator
Operator
Our next question is from John Kreger with William Blair.
我們的下一個問題來自 William Blair 的 John Kreger。
John Charles Kreger - Partner & Healthcare Services Analyst
John Charles Kreger - Partner & Healthcare Services Analyst
Joe, given the very strong growth that you just finished up in '17, how do you feel about the manufacturing infrastructure's ability to handle it? If you had similar growth in '18, as you just put up, would there be any strains on the system, in Juarez, in particular? And do you have to put some more capital work there to stay ahead of that?
Joe,鑑於你們剛在 2017 年完成非常強勁的成長,你對製造基礎設施的承載能力有何看法?如果 2018 年也有你們剛達成的類似成長,系統是否會有任何壓力,特別是在 Juarez?你們是否需要在那裡投入更多資本支出以提前因應?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
John, yes, we do. I mean, we do that almost systematically. We make sure that we have enough SLA equipment and capability in Juarez, obviously, we're going to have extra capacity now coming on in China that will help to take some pressure off that facility, too. We also could have a bottleneck on the patient on the -- when you look at Costa Rica and what we do overall from the case assessment and a case prescription standpoint. But we tend to stay up with that. And we had a big challenge last year because we had a lot of volume come at us pretty quickly, and we were able to recover and get that done. So I think, John, right now, I feel good about our operations team, our ability to anticipate that to have that kind of capacity available upfront to get this done. So we don't look at that as being an issue in 2018.
John,是的,我們會。我的意思是,我們幾乎是系統性地在做這件事。我們會確保在 Juarez 有足夠的 SLA 設備與產能;當然,我們現在也會在中國新增額外產能,這也會幫助分擔那座廠的壓力。另外,從病患端來看——當你看 Costa Rica 以及我們整體在病例評估與處方制定(case prescription)方面所做的工作——也可能出現瓶頸。但我們通常都會跟上需求。去年我們遇到很大的挑戰,因為有大量需求在很短時間內湧入,但我們也成功恢復並把它完成。所以我想,John,就目前而言,我對我們營運團隊、以及我們預先預判並提前備妥這類產能的能力感到有信心,能把這件事做好。因此我們不認為 2018 年這會是個問題。
John Charles Kreger - Partner & Healthcare Services Analyst
John Charles Kreger - Partner & Healthcare Services Analyst
Great. And then just 1 follow-up. Can you talk a bit key new innovations? So you gave us a nice update on mandibular advancement. As we think about '18, is there anything else on the horizon that you maybe care to preview?
很好。接著再追問一題。你能談談一些關鍵的新創新嗎?你剛剛對下顎前移(mandibular advancement)給了我們很好的更新。當我們看 2018 年時,還有沒有其他即將推出、你願意先預告的內容?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Well, I think we've talked a lot about rapid palate expansion. I mean, we talked about that about 18 months ago. We've been given updates on that. That technology continues to progress. We're enthusiastic about it. That's rapid palate expansion, John. We do -- you put in, in this case, a device, it replaces a device where you use, actually, a wrench today to turn it. It's very crude in a sense of how you expand the palate. This would be a digital way with plastic being able to expand the palate on a regular basis. We also have a product called dental expansions, which would expand your upper jaw also with Invisalign -- with Invisalign aligners also. So those are the big products that we're moving toward. When you think about the teen marketplace that we call tweens and teens, and 30% of that marketplace is basically rapid palate expansion and MAF, mandibular Phase I kind of things. So that technology is really aimed at making us have a more substantial footprint and capability in that teen segment.
嗯,我想我們談了很多快速顎擴張(rapid palate expansion)。我的意思是,我們大約在 18 個月前就談過。我們也一直提供這方面的更新。那項技術持續在進展。我們對此感到很振奮。那就是快速顎擴張,John。我們會——在這個案例中,你會放入一個裝置,它取代了目前需要用扳手去轉動的裝置。就某種意義而言,現在擴張上顎的方式非常粗糙。而這會是一種數位化的方法,透過塑膠材質能夠定期擴張上顎。我們也有一個產品叫做牙弓擴張(dental expansions),也能用 Invisalign——用 Invisalign 隱形牙套來擴張你的上顎。所以這些是我們正在推進的主要產品。當你想到我們稱之為 preteens 與 teens 的青少年市場,其中 30% 基本上是快速顎擴張與 MAF、也就是下顎第一期(mandibular Phase I)這類治療。因此,這項技術真正的目標,是讓我們在青少年區隔中擁有更實質的佈局與能力。
Operator
Operator
Our next question is with Jeff Johnson with Baird.
我們的下一個問題是 Baird 的 Jeff Johnson。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
So most of my questions have been answered. But, John, I think it was you who mentioned on SDC maybe revenues coming down a little bit in the forward quarters here after a couple of quarters in a row near $10 million as they continue to ramp their aligner manufacturing. I guess my question, just why do they keep investing in manufacturing capacity? Obviously, they have a good partner in you guys. You guys have plenty of manufacturing. I know maybe some strain on it in Juarez as we were just discussing. But why the investments there still? And why not just continue to use you guys for most of their aligner needs?
所以我大部分的問題都已經被回答了。不過,John,我想是你提到 SDC 的部分,隨著他們持續擴增其牙套製造產能,在連續幾季接近 1,000 萬美元之後,未來幾季營收可能會稍微下滑。我想問的是,他們為什麼還要持續投資製造產能?顯然你們是很好的合作夥伴。你們也有充足的製造能力。我知道也許 Juarez 那邊會有一些壓力,正如我們剛剛討論的。但為什麼他們仍然要在那邊投資?為什麼不乾脆繼續主要使用你們來滿足他們大部分的牙套需求?
John F. Morici - CFO
John F. Morici - CFO
Jeff, I think it's -- I think it looks -- it's a separate company, they're looking at this as how they want to run their company and decisions that they make to invest and produce their own product. We take anything that comes externally from -- that they don't want to manufacture. And it varies as you've seen kind of quarter-by-quarter based on what they produce versus what they go outside with. But it's just an internal decision that they make.
Jeff,我想——我想看起來是這樣:那是一家獨立公司,他們會從如何經營公司、以及他們要投資並生產自有產品的決策角度來看這件事。他們不想自行製造的部分,我們就承接任何外部轉來的需求。而且如你所見,這會依季度而有所不同,取決於他們自己生產多少、以及有多少會外包。但這就是他們內部所做的決策。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Okay. Fair enough. And then when I try to triangulate, I take your 1Q guide, kind of your 1H versus 2H EBIT guide and think about kind of what's going on in the business right now, help me out just understand what looks like it could be a down margin in the first quarter. And I know John is going to give you pass on that, but let me just push a little bit on it. How much of that is just your opening in Cologne recently, opening in China and the treatment planning, China manufacturing costs or manufacturing facility being built out? It just seems like you are doing quite a bit right now, a couple of new storefronts and all that stuff. Is that really the driver of just some elevated expenses here in the near term? Or should we be thinking anything ASP-driven or anything else kind of core fundamental to the business just versus some investments that need to be made right now?
好的。可以理解。接著當我嘗試交叉推算時,我把你們第一季的指引、你們上半年相對下半年的 EBIT 指引,以及目前業務的狀況放在一起看,請幫我理解一下:第一季看起來可能會出現較低的毛利率/利潤率。我知道 John 可能會略過這題,但我還是想再追問一下。其中有多少只是因為你們最近在科隆開幕、在中國開點,以及治療規劃、在中國的製造成本或製造設施的建置?看起來你們現在同時在做很多事,幾個新的門市等等。這是否真的是短期費用偏高的主要驅動因素?還是我們應該考慮任何由 ASP(平均售價)驅動的因素,或其他更核心、基本面的業務因素,而不只是目前必須投入的投資?
John F. Morici - CFO
John F. Morici - CFO
Yes, Jeff. It's mostly investments. If you think about how 2017 played out from the investments early on in the year and progressively as we went quarter-by-quarter, we got increasing operating leverage. It's the same type of play that we would have for 2018. We're investing, we continue to follow the strategy that we have and you'll see those investments throughout the year. And first quarter, it's not as much operating leverage, but to guide something flat on a year-over-year basis around that 24%, you would expect to see some of that increase as we go through the year.
是的,Jeff。主要是投資。如果你回想 2017 年的走勢,從年初的投資開始,並且隨著我們一季一季推進,我們獲得了愈來愈高的營運槓桿。2018 年我們也會採取同樣的策略。我們在投資,並持續遵循既定策略,你會在全年看到這些投資。第一季的營運槓桿沒有那麼多,但若我們指引年對年大致持平、約在 24% 左右,你會預期隨著年度推進,這個數字會有所提升。
Operator
Operator
Our next question is with Matt O'Brien with Piper Jaffray.
我們的下一個問題來自 Piper Jaffray 的 Matt O'Brien。
Kevin Michael Farshchi - Research Analyst
Kevin Michael Farshchi - Research Analyst
This is Kevin on for Matt today. I wanted to follow up on a previous question on manufacturing. I know China, the facility there is coming on later this year. I was just curious on the primary investments there. Are there any updates to new printers or materials and, I guess, more broadly with the large growing cash balance and possible repatriation of some cash back into the U.S., how the company thinks about the best use of cash at the moment?
我是今天代替 Matt 的 Kevin。我想跟進先前關於製造的問題。我知道中國那邊的廠房會在今年稍晚啟用。我想請教那邊主要的投資項目是什麼。在新印表機或材料方面是否有任何更新?另外更廣泛地,隨著現金餘額大幅成長,以及可能將部分現金匯回美國,公司目前如何看待現金的最佳用途?
John F. Morici - CFO
John F. Morici - CFO
Yes. I could start with that one. I mean, when we think about our China operation, I mean, when we -- as kind of have been noted, when we talk about investments that we have to make to make up -- to accommodate the manufacturing, we're always investing. So now we're going to add to that capacity that we need in China. So it's really a shift, in some cases, from Mexico to China, and we'll continue to make those investments as needed from an overall growth standpoint. And when we look at our cash position that we have, as we said on the -- previously, we're going to look at what strategically makes the most sense to bring cash back where we need it, where we can properly use that cash for future investments. But in other cases, like China, we'll leave cash there to be able to grow that operation that we need. So we're going to look at this very strategically as to how we best fund our growth.
是的。我可以先回答這題。我的意思是,當我們思考中國的營運時——如同先前提到的,當我們談到為了補足——為了配合製造所必須進行的投資時,我們一直都在投資。所以現在我們要在中國增加我們所需的產能。因此在某些情況下,這其實是從墨西哥轉移到中國,我們也會從整體成長的角度,視需要持續進行這些投資。至於我們的現金部位,如同我們先前在——先前所說,我們會評估從策略上最合理的方式,把現金帶回我們需要的地方,並在那裡妥善運用這些現金進行未來投資。但在其他情況下,例如中國,我們會把現金留在當地,以便擴張我們所需的營運規模。因此我們會非常策略性地評估,如何以最佳方式為成長提供資金。
Kevin Michael Farshchi - Research Analyst
Kevin Michael Farshchi - Research Analyst
Okay, great. And then lastly, I was just looking at the percentage of cases done through the iTero digital scanning process. It goes up nicely every quarter, and it was right around 50% in North America this time last year, so large incremental improvement. Ideally, you're looking for 100% there, but is there an internal target that the company is looking for in '18 or the coming years? And secondly, how would you think about any kind of savings from fewer adjustments being sent back or shipping the molds out? Is it more significant than we might assume?
好的,很棒。最後,我在看透過 iTero 數位掃描流程完成的案例占比。每一季都提升得很好,而去年此時在北美大約是 50%,所以增量改善很大。理想上你們會希望達到 100%,但公司在 2018 年或未來幾年是否有內部目標?第二,你會如何看待因為回寄調整件變少或寄送模型變少所帶來的任何節省?它是否比我們可能假設的更顯著?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
It's Joe. We really don't set numbers year-to-year to think where we're going to be, but you saw a 10-point increase last year in North America alone. So I mean, we expect that going forward. As scanners are more and more adopted, obviously, fewer impressions are going to be done. So I mean, ideally, you'll get to 100% some day. But getting to 80%, 85% is probably going to be at the top of the area, because a lot of -- particularly on the GP side, we'll be maybe reluctant to invest in the scanner until they know that they have enough Invisalign volume to really support that. But as far as the savings of doing that, we actually -- obviously, you don't have -- you have better fitting aligners. We know all those things occur from that, but we don't have any quantification in a sense of the economics or changes in that way that I can share with you, that I know.
我是 Joe。我們其實不會逐年設定數字來思考我們會到哪裡,但你看到去年光是在北美就增加了 10 個百分點。所以我的意思是,我們預期未來也會如此。隨著掃描器被愈來愈多採用,顯然會有更少的傳統印模。所以理想上,有一天會到 100%。但到 80%、85% 可能會是相對高的區間,因為很多——特別是在一般牙科(GP)端,他們可能會對投資掃描器較為猶豫,直到他們確定 Invisalign 的量足以真正支撐這項投資。至於這樣做的節省,我們其實——顯然,你會有——更貼合的牙套。我們知道這些事情都會因此發生,但我沒有任何可與你分享的量化數據,從經濟性或那方面的變化來說,我所知道的就這些。
Operator
Operator
Our last question is with Brandon Couillard from Jefferies.
我們最後一個問題來自 Jefferies 的 Brandon Couillard。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
Just a couple of housekeeping questions, John. In terms of the 1Q revenue guidance, $400 million to $410 million, pretty rare that we see a sequential quarter-to-quarter decline, if ever, does that imply -- can you give us some sense of like the actual magnitude of the scanner step-down from 4Q into the first quarter and perhaps spike out whether that largely reflects upfront Patterson shipments that really won't recur in the first quarter?
John,我有幾個例行性問題。就第一季營收指引 4.00 億到 4.10 億美元而言,我們很少看到季度環比下滑(如果有的話),這是否意味著——你能否讓我們了解一下掃描器從第四季到第一季實際下滑的幅度?以及是否主要反映了 Patterson 在第四季的前置出貨,而這在第一季不會再發生?
John F. Morici - CFO
John F. Morici - CFO
Yes, Brandon, it's -- yes, as you pointed out, the revenue is -- the numbers that we guided to is just a pure reflection of what we expect from a scanner standpoint and being the strength of Q4 from a scanner standpoint. A big quarter from a capital standpoint and investment standpoint by our doctors doesn't necessarily repeat in Q1. So that's a step-down that we see. So it's really what's driving that change and that it's not unexpected in terms of how we look at Q4 to Q1.
是的,Brandon,這——是的,如你所指出的,我們所給的營收——我們所提供的指引數字,純粹反映了我們對掃描器面向的預期,以及第四季掃描器面向的強勁表現。醫師在資本支出與投資面向的一個大季度,不一定會在第一季重演。所以我們看到會有這樣的下滑。因此真正驅動這個變化的就是這點,而且就我們看待第四季到第一季的方式而言,這並不意外。
Brandon Couillard - Equity Analyst
Brandon Couillard - Equity Analyst
And then secondly, in terms of the '18 outlook, could you give us a sense of where you see your percentage of SmileDirect manufacturing volumes shaken out for the year? And then secondly, curious if you've finalized plans of whether you expected to take some more list pricing this year.
第二,關於 2018 年展望,你能否讓我們了解一下你預期今年 SmileDirect 的製造量占比會落在什麼水準?另外,也想請教你們是否已敲定今年是否會再進行一些牌價(list pricing)調整。
John F. Morici - CFO
John F. Morici - CFO
So on SmileDirectClub, we would expect about the same volume year-over-year. So what we saw in '17 should approximately repeat in 2018, and that would be included in the overall numbers that we gave. And in terms of ASPs, we've increased in the past, we haven't announced any increase in 2018. We'll let our customers know in advance and then communicate that afterwards, but our past history has been to (inaudible).
關於 SmileDirectClub,我們預期年對年大致相同的量。所以我們在 2017 年看到的情況,2018 年應該會大致重複,而這也已包含在我們所提供的整體數字之中。至於平均售價(ASP),我們過去曾經調升,但我們尚未宣布 2018 年會調升。我們會提前通知客戶,之後再對外溝通,但我們過去的做法是(聽不清楚)。
Shirley Stacy
Shirley Stacy
Okay. Thank you, everyone. Sorry, operator. Thanks, everyone. This concludes our conference call today. We look forward to seeing you at upcoming financial conferences and industry meetings, including the Leerink Healthcare Conference, Morgan Stanley, European Healthcare Conference and the Chicago Midwinter Meeting. We're also announcing today that we will be hosting an Investor Day in New York City on May 23. Additional information will be available shortly. We hope to see you there. If you have any questions, please contact Investor Relations. Thanks, and have a great day.
好的。謝謝各位。抱歉,接線員。謝謝大家。今天的電話會議到此結束。我們期待在接下來的財務研討會與產業會議上與各位見面,包括 Leerink Healthcare Conference、Morgan Stanley、European Healthcare Conference 以及 Chicago Midwinter Meeting。我們也在今天宣布,將於 5 月 23 日在紐約市舉辦投資人日(Investor Day)。更多資訊將於近期提供。希望到時見到各位。如有任何問題,請聯絡投資人關係部門。謝謝,祝各位有美好的一天。
Operator
Operator
This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.
今天的電話會議到此結束。您現在可以掛斷電話。感謝您的參與。